Annually, over 500 000 men worldwide are diagnosed with prostate cancer, which is rapidly becoming the most common male cancer, due to an ageing population and increased detection through serum prostate-specific antigen (PSA) testing. However, the aetiology of prostate cancer is poorly understood and there are limited prospects for primary prevention ([@bib18]). Serum PSA testing followed by transrectal ultrasound-guided needle biopsy identifies cancers localised to the prostate gland, and could form the basis of a screening programme to detect disease amenable to cure. However, since many potentially identifiable prostate cancers are indolent ([@bib38]), over-diagnosis and over-treatment ([@bib16]; [@bib40]), which can impact adversely on a man\'s quality of life, are major concerns ([@bib32]).

Two recently published randomised controlled trials of PSA-based screening ([@bib2]; [@bib41]) failed to resolve the controversy over the effectiveness of screening in reducing mortality and improving quality of life ([@bib32]). In the primary analysis of the European Randomised Study of Screening for Prostate Cancer (ERSPC), a 20% reduction in prostate cancer mortality was observed after a median follow-up of 9 years, with PSA testing every 4 years *vs* no screening ([@bib41]). The effect estimates were imprecise, however, with the 95% confidence limits indicating that the benefit could be as much as 35% or as little as 2%. The absolute reduction in risk suggested that 1410 men would need to be screened and 48 cancers detected to prevent one death from prostate cancer at approximately 8 years following diagnosis. A further analysis with median follow-up of 11 years ([@bib42]) yielded a similar 21% relative reduction in prostate cancer mortality and a slightly improved absolute benefit (1055 men would need to be screened and 37 cancers detected to prevent one death from prostate cancer). A microsimulation study based on ERSPC data suggested that 43% of cancers detected by screening are overdiagnosed and that the mortality benefits are diminished by a 23% reduction in quality-adjusted life-years because of the adverse effects of treatment ([@bib23]).

The PLCO (prostate, lung, colon and ovarian cancer screening) trial reported no mortality benefit from screening after 7 ([@bib2]) or 13 years ([@bib3]) of follow-up. However, there are relatively few prostate cancer deaths reported to date. In addition, high levels of non-compliance in the intervention arm and contamination by widespread PSA testing in the control arm, make it unlikely that the PLCO trial can accurately estimate the magnitude of the intervention effect ([@bib21]).

A recently updated Cochrane review ([@bib26]) of five randomised controlled trials, a meta-analysis ([@bib13]) of six randomised controlled trials, including the ERSPC, PLCO and 20-year-follow-up of a small, long-term trial ([@bib39]) do not provide strong evidence that screening causes reductions in all-cause or prostate cancer-specific mortality that are important enough to outweigh potential harms. The recent updated report from the US Preventive Services Task Force recommended against routine PSA-based screening ([@bib9]). However, the controversy surrounding these draft recommendations ([@bib8]; [@bib30]) suggests continuing concerns about the methodological quality of some evidence and associated risks of bias. These concerns are reinforced by favourable modelling projections ([@bib20]) and secondary analyses ([@bib37]); thus, the benefits and harms of population or targeted prostate cancer screening remain uncertain.

The most effective treatment for PSA-detected localised prostate cancer is also unknown because treatment within published screening trials was not randomised, and published treatment trials are difficult to interpret in relation to screening and the known heterogeneity of the disease. The findings from the SPCG-4 trial (comparing radical surgery and watchful waiting) provide robust evidence of a reduction in prostate cancer mortality in those assigned to radical surgery, but few men were recruited by PSA testing ([@bib24]). The PIVOT trial did not provide conclusive evidence that older men with higher risk tumours (mean age 67 years, 48% Gleason 7 or higher, 66% intermediate/high risk) benefit from radical surgery compared with observation ([@bib50]). Neither trial has clear application for younger men with predominantly low-risk tumours in contemporary PSA-detected cohorts.

Here, we report the design, methods and results of recruitment in the CAP (Cluster randomised triAl of testing for Prostate cancer) trial. CAP is a nationwide, primary care-based cluster RCT that evaluates whether PSA testing of men aged 50--69 years will reduce prostate cancer mortality and be cost-effective (ISRCTN92187251). The embedded ProtecT trial ([@bib14]; [@bib28]) (ISRCTN20141297) compares the effectiveness and cost-effectiveness of radical prostatectomy, radical conformal radiotherapy and active monitoring (regular PSA testing and treatment review) in men with PSA-detected clinically localised prostate cancer. The CAP trial will estimate the effect of a policy to invite men aged 50--69 years for PSA testing.

Materials and Methods
=====================

Study design
------------

CAP is a pragmatic cluster RCT, testing effectiveness in everyday practice by comparing an invitation to attend for population-based PSA testing for prostate cancer (the ProtecT trial intervention arm) with standard UK National Health Service (NHS) care (control arm) in men aged 50--69 years registered with general practices (community-based primary care clinics) in and around eight cities in England and Wales: Birmingham, Bristol, Cambridge, Cardiff, Leeds, Leicester, Newcastle and Sheffield ([Figure 1](#fig1){ref-type="fig"}).

Cluster randomisation
---------------------

General practitioner (GP) practices (the cluster unit) were randomised between 2001 and 2007 by a statistician not otherwise involved in the study before their recruitment ('Zelen\' design ([@bib51])). Randomisation was blocked and stratified by geographical area based on groups of 10--12 neighbouring practices and using a computerised random number generator to allocate a near-equal number of practices in each stratum to intervention and comparison arms. Where a stratum contained an odd number of practices, the greater number of practices was randomised to the intervention arm to support recruitment to the embedded ProtecT treatment trial.

Recruitment of GP practices
---------------------------

Randomised practices were contacted by a researcher who briefed the GPs primary care doctors and practice managers, following which an information and consent pack was sent, tailored to the allocated arm. A senior partner (or equivalent) was asked to provide written consent for participation in the study, acting as a 'guardian\' of the interests of individuals currently registered at the practice who would be involved in the study. Practices who contemporaneously recruited men to a trial of rofecoxib in the prevention of prostate cancer (Vioxx in Prostate Cancer Prevention study ([www.clinicaltrials.gov/show/NCT00060476](http://www.clinicaltrials.gov/show/NCT00060476)) were excluded. Control arm practices within clusters where no intervention arm practices were recruited, and intervention arm practices in clusters where no control arm practices were recruited, were also excluded.

The success of randomisation and the impact of post-randomisation exclusions or dropouts were assessed by comparing routinely available practice level variables between the trial arms: list size; index of multiple deprivation (IMD) scores at lower level super output area ([@bib27]) based on practice postcode; urban--rural classification ([@bib47]); and mean prevalence of cancer, diabetes, obesity and coronary heart disease, based on data routinely submitted to the NHS Quality Outcomes Framework by GP practices ([@bib36]).

Recruitment of participants
---------------------------

Recruitment to the intervention arm has been described in detail elsewhere ([@bib15]; [@bib28]). Briefly, in each intervention arm practice, men aged 50--69 years were identified from the computerised patient lists on a specific date ([@bib28]) (the 'list date\'). Each man was sent a single invitation by letter to attend a nurse-led prostate-check clinic appointment where the potential benefits and harms of having a PSA test were explained, and written informed consent was obtained. There was a second consent form completed after 24 h for all men who agreed to PSA testing. Men who attended the prostate-check clinic were also asked whether they would consent to being traced and flagged for vital status follow-up with the Health and Social Care Information Centre (HSCIC).

In control arm practices, all men aged 50--69 years registered with each practice on a pre-specified date (consistent with the list dates in intervention arm practices within the same stratum) were eligible for inclusion. Men were not individually invited to participate as they were undergoing standard NHS management. However, they (and intervention arm non-responders) were given the opportunity to opt out of follow-up with the HSCIC through information provided at each practice.

Lists of all men aged 50--69 years who were registered at the intervention and control arm practices on the 'list dates\', and who had not opted out, were obtained through each practice computer system and the following data were extracted: name, postcode, date of birth, NHS number and practice identification number. These data were encrypted and returned to the co-ordinating centre (School of Social and Community Medicine, University of Bristol). These lists constitute the CAP trial cohort for follow-up.

Trial interventions
-------------------

In the intervention arm, men with a raised PSA (⩾3.0 ng ml^−1^) were invited for diagnostic tests including a transrectal ultrasound (TRUS)-guided biopsy. All men subsequently diagnosed with clinically localised prostate cancer (T1-T2, NX, M0) were asked to consider randomisation within the ProtecT three-arm trial of treatments: radical prostatectomy, radical conformal radiotherapy and active monitoring (regular PSA testing and review). If randomisation was unacceptable, a patient preference treatment option was agreed ([@bib15]; [@bib28]). Men found to have advanced disease were treated in the NHS urology clinics of the recruiting centres. All men treated via randomisation or by preference were followed up in annual nurse-led clinics.

Control arm practices were supplied with contemporary information from the NHS prostate cancer-risk management programme ([@bib33]) to encourage standard NHS management, including the provision of standardised information about the potential benefits and harms of PSA testing for any man over the age of 50 years who requested a PSA test.

Follow-up and identification of a prostate cancer-related event
---------------------------------------------------------------

Surveillance for relevant outcomes is passive, triggered by the occurrence of death or cancer registration identified via flagging with the HSCIC. When such triggers are received, clinical and resource-use data from the man\'s medical records are obtained, blind to the cancer registry or death certificate information. Data items include: symptoms and signs of prostate cancer presence and progression; diagnostic and monitoring tests; histology, tumour stage; treatments received and the outcomes of treatment; complications related to prostate cancer diagnosis or treatment; co-morbidities; and other resource-use data (e.g., length of inpatient stay, outpatient appointments). For men who have died, a researcher, blind to information on the death certificate, prepares a short-structured vignette that summarises the key clinical events from diagnosis to death.

Determination of cause of death
-------------------------------

To minimise potential attribution bias ([@bib1]; [@bib7]), an international Cause of Death Evaluation (CODE) Committee reviews clinical information abstracted from medical records (vignettes) on all possible prostate cancer deaths in both arms of the trial (independent chair: professor Peter Albertsen, Connecticut, USA). A list of specific ICD9 and ICD10 codes, adapted from those used by the PLCO Screening Trial ([@bib31]), is used to identify a possible prostate cancer event from the ICD codes listed in parts I and II of each man\'s death certificate. The following outcomes are assigned by the reviewers (blind to trial arm and information on the death certificate), according to pre-defined definitions adapted from those used in the ERSPC trial ([@bib11]): definite, probable, possible, unlikely or definitely not prostate cancer; and definite or probable intervention-related mortality. Further information about the CODE process and algorithm will be published separately.

Primary and secondary outcome measures
--------------------------------------

The primary outcome is 'definite\' or 'probable\' prostate cancer mortality after a median 10-year-follow-up, which will occur in 2016. Secondary outcomes include all-cause mortality at median follow-up of 10 and 15 years; definite or probable prostate cancer mortality at 15 years; disease status and staging; and cost-effectiveness. Sensitivity analyses will restrict prostate cancer mortality to deaths classified as definite prostate cancer and widen the definition to include definite, probable and possible prostate cancer deaths. The impact of PSA testing on health-related quality of life has been investigated in a linked study ([@bib5], [@bib6]; [@bib29]).

Assessment of contamination
---------------------------

The level of PSA testing from a convenient sample of 87 control arm general practices in 2007 was collected using the EMIS LV computer system. Information for a total of 126 716 men aged 45--89 years with no recorded diagnosis of prostate cancer before 1 January 2007 was collected and has been reported previously ([@bib49]). Further studies of contamination are underway.

Ethics and research governance
------------------------------

Men who attended the prostate-check clinic in the intervention arm gave individual informed consent (Trent MREC/01/4/025). Approval for flagging of men in the control arm and non-responders in the intervention arm was obtained under Section 251 of the NHS Act 2006 (PIAG 4-09 (k)/2003) from the UK Patient Information Advisory Group (PIAG) (which became until recently the National Information Governance Board Ethics and Confidentiality Committee, NIGBECC). Trent MREC provided ethics approval for flagging (MREC/03/4/093) and review of the medical records of men with prostate cancer (05/MRE04/78). Men who were alive when we were notified of a prostate cancer diagnosis provided individual informed consent for review of their medical records. PIAG/NIGBECC approval allows review of the medical records of men who died of a cause potentially related to prostate cancer before consent could be gained (provided the man did not record an objection to their medical records being used for research while alive) (PIAG 1-05(f)/2006). All clinical centres have local research governance and ethics approval. The CAP study is sponsored by the University of Bristol and funded by Cancer Research UK and the Department of Health.

Analysis plan
-------------

The primary analysis will be by intention-to-screen: all men followed up in the intervention arm will be included in that arm for analysis regardless of whether or not they responded to the invitation to have a PSA test. Similarly, control arm men will be included in that arm regardless of whether they had a PSA test. The effect of an invitation to screening on prostate cancer mortality will be estimated as a rate ratio while allowing for clustering by general practice once a median of 10 years follow-up data has accumulated. Analyses will be adjusted for randomisation strata.

Follow-up will commence on the 'list date\' for each practice. Men will be excluded from the analyses if they had prevalent prostate cancer (diagnosed at or before the list date). Men will be censored on the date of death, or date of loss to follow-up (e.g., notified by the HSCIC as having emigrated). This approach to analysis will be adapted to the secondary outcome measure, such as all-cause mortality. Sensitivity analyses will assess whether controlling for any baseline imbalances in practice characteristics makes any difference to the estimated effects of screening.

If any of the three treatment arms in the ProtecT trial is superior (leads to lower mortality compared with the other arms), differences in prostate cancer or all-cause mortality between the CAP trial arms may be smaller than would be expected if a screening programme had used the optimal treatment(s). We will estimate the effect on mortality of such an 'optimal\' screening programme, based on the (unbiased) treatment effect estimates from ProtecT and the (unbiased) overall effect estimates from CAP. Similar to what has been done for the ERSPC study ([@bib37]), we will use appropriate methods to estimate the effect of testing in those who undergo PSA measurement (complier average causal effect). This can be used to predict the overall effect of a screening programme under different assumptions about uptake of PSA testing and subsequent treatment.

Sample size and power
---------------------

The sample size of the CAP trial was determined by the number of practices required to meet the recruitment target for the embedded ProtecT trial. Power calculations assessed whether this would be sufficient to detect reductions in prostate cancer mortality of a magnitude likely to be important to the NHS ([@bib19]; [@bib4]). We considered a range of plausible between-practice coefficients of variation (a measure of the amount of between-practice variation in prostate cancer mortality rates). For example, based on estimates of the incidence of prostate cancer mortality (the primary outcome) over 10 years using 2006 England and Wales incidence and mortality data ([@bib34]), and assuming a plausible coefficients of variation of 0.2, 209 000 men in each study arm allows a true overall prostate cancer mortality rate ratio of 0.87 to be detected with 80% power at 5% significance. This corresponds to an intervention rate ratio among men undergoing screening (IRR) from 0.62 to 0.73, assuming uptake of the invitation to PSA testing of 35% and 50%, respectively. These IRRs are similar to those assumed in the power calculations for the ERSPC trial ([@bib12]), where post-consent randomisation ensured most men would undergo testing. Our estimates of the impact of a range of PSA contamination rates (defined as ever having a PSA test during follow-up, as in ERSPC ([@bib12])), suggest that the effect of contamination is minimal unless it reaches 20%, a level unlikely in this trial ([@bib49]).

Results
=======

Recruitment
-----------

### GP practice recruitment

In total, 911 GP practices were randomised in 99 geographical areas. Six areas (52 practices) were excluded from further analysis as no intervention or control arm practices were recruited (see [Figure 2](#fig2){ref-type="fig"}). Of the 440 practices in the intervention arm and 419 in the control arm, 42 and 32 (respectively) were ineligible, because the GP practice was involved in the Vioxx trial, had ceased to exist, consented too late to allow participation, exclusively covered an atypical population (e.g., private, asylum seekers, children in care, homeless, sheltered housing), could not produce a list of men aged 50--69, or had been randomised in error (i.e., practices that participated in the feasibility phase of the ProtecT trial ([@bib14])). Of the remaining 398 intervention arm and 387 control practices, 42 and 40, respectively, explicitly refused to participate, while 85 and 45, respectively had not responded after being allowed at least one year to consider taking part (and can be considered as implicit refusals, generated by the way the study was carried out). There was little evidence of differences between measured characteristics of the 573 participating practices and the 130 implicit refusal practices (list size 6827 *vs* 7264 (*P*=0.4); IMD English 29 *vs* 27 (*P*=0.3); IMD Wales 21 *vs* 23 (*P*=0.8); number of urban practices 88% *vs* 82% (*P*=0.07); cancer prevalence 0.55% *vs* 0.54% 9 (*P*=0.7); diabetes prevalence 3.7% *vs* 3.6% (*P*=0.7); obesity prevalence 7.9% *vs* 8.5% (*P*=0.08); coronary heart disease 4% *vs* 3.8% (*P*=0.2), respectively). Where practices explicitly refused, the major reasons were lack of interest, time or space ([@bib17]). Thus, among the eligible practices, 271 (68%) in the intervention arm and 302 (78%) in the control arm consented to participate.

We found little evidence of differences between the measured characteristics between the 785 eligible practices randomised to the intervention compared with control arms. Neither did we find evidence of differences in measured characteristics between the practices who consented to participate in the intervention compared with control arms ([Table 1](#tbl1){ref-type="table"}).

### Take-up of PSA testing

Among 197 925 eligible men in the intervention arm, 16 752 were not invited for a PSA test because they met ProtecT study exclusion criteria (they were excluded by their GP because of terminal or severe mental illness, serious co-morbidity or pre-existing prostate cancer diagnosis). However, these men are included in the follow-up for prostate cancer incidence and mortality via the HSCIC. A further 1404 men were excluded as they had prevalent prostate cancer and the HSCIC could not trace 47 men, these figures are subject to change as a result of continued updates from the HSCIC. Of the remaining 179 722 men who received an invitation to PSA testing within the intervention arm, 79 989 (45%) attended a prostate-check clinic and 65 113 (36%) men gave full consent for their PSA level to be measured as part of the ProtecT study.

In the control arm among 221 629 men, three men opted out, 1632 had prevalent prostate cancer and HSCIC failed to trace 81, as above these figures are subject to change upon receipt of further information from the HSCIC. Thus, a total of 416 387 men were randomised into the intervention and control arms ([Figure 2](#fig2){ref-type="fig"}), a population-based sample covering approximately 8% of the England and Wales male population aged 50--69 years ([@bib36]). Consent rates for flagging with the HSCIC were over 99%, and 97.5% of men were matched to the NHSCR database automatically with 2.5% requiring manual matching. There were no substantial differences between the men in the intervention and control arms in terms of age (mean 59.1), baseline prevalence of prostate cancer (prostate cancer diagnosed before randomisation was 0.71% in the intervention arm compared with 0.74% in the control arm) or index of multiple deprivation score, a census-derived measure of multiple aspects of area-level deprivation, in England (22.9) or Wales (20.8 *vs* 19.6, respectively).

Discussion
==========

The CAP trial recruited successfully over 415 000 men from 573 primary care practices across the UK. Its future contribution to the evidence base is illustrated by the ways in which it differs in methods of recruitment, screening and treatments offered compared with the two major published screening trials (summarised in [Table 2](#tbl2){ref-type="table"}; [@bib43]). Cluster randomisation makes estimation of the effect of a policy to invite men for screening easier, enhancing the trial\'s generalisability beyond men consenting to individual randomisation. An 'intention-to-screen\' analysis will ensure that individuals will be analysed in the arm their GP practice was allocated to, regardless of whether or not they received the intervention.

A major strength, not available to any of the other screening trials, is that the three-arm ProtecT trial will establish the relative effectiveness and cost-effectiveness of treatments for PSA-detected disease in men diagnosed with clinically localised prostate cancer, including a contemporary programme of active monitoring ([@bib16]), thus enabling the determination of the most effective and cost-effective treatment following PSA testing. ProtecT will assess how active monitoring compares with radical surgical and radiation therapy, and the balance of benefit to harm for these patients. Estimates of the effect on mortality of an 'optimal\' screening programme will be provided based on the (unbiased) treatment effect estimates from the ProtecT trial of treatments and the (unbiased) overall effect estimates from CAP.

Cluster randomisation was used because PSA testing was offered to all men in intervention arm practices where individual randomisation would have been impracticable. Compared with an individually randomised design, the clustered design reduces the likelihood of contamination in the control group: only 6.2% of men (95% confidence interval: 5.7--7.0% practice-based interquartile range 3.6--8.4%) had their PSA tested in 2007 in a sample of control arm CAP practices ([@bib49]), in line with published studies (2--9% in any one year ([@bib35])). Further assessments of contamination are ongoing to estimate more precisely the proportion of control men undergoing one or more PSA tests during the 10-year study period.

Randomisation of general practices was carried out before consent to participate, because of logistical requirements related to the recruitment process in the ProtecT trial. Consent rates amongst eligible practices in the intervention and control arm were 68% and 78%, respectively. We found little evidence of differences between the intervention and control arms at baseline at either an individual or practice level. It is not possible to exclude the possibility that post-randomisation exclusions introduced selection bias. Nonetheless, the large number of practices randomised and the stratified randomisation scheme should ensure that practices are approximately balanced with respect to potential prognostic factors at the time of randomisation. A further strength is that intervention and control arm men were traced and flagged with the HSCIC, ensuring an unbiased intention-to-screen analysis, comparing outcomes for the two arms of the trial according to the original random allocation.

The CAP trial aims to evaluate the impact of population-based PSA testing for prostate cancer--a test with acknowledged limited specificity ([@bib25]), imperfect sensitivity (15.2% of men with a PSA level of 4.0 ng ml^−1^ or less biopsied at the end of follow-up in the Prostate Cancer Prevention Trial were diagnosed with prostate cancer, with high-grade cancers (at least Gleason 7) observed throughout this range of PSA values) ([@bib46]), and a high rate of over-diagnosis of low-risk disease resulting in over-treatment. Currently, however, there are no alternative reliable screening methods. The modest PSA testing rate in the intervention arm reflects that achievable with a single invitation to eligible participants, but randomisation allows us to employ appropriate statistical methods (e.g., complier average causal effects, contamination-adjusted ITT ([@bib45])) to estimate the effect in those who undergo PSA testing ([@bib10]; [@bib37]). This can be used to predict the overall effect of a screening programme under different assumptions about PSA uptake. We will not be able to measure quality of life in the men being followed up passively; however, a linked study has investigated the impact of PSA testing on health-related quality of life in men followed up in the intervention arm ([@bib5], [@bib6]; [@bib29]).

ERSPC ([@bib41]) and PLCO ([@bib2]) included various screening intervals, ranging from 2 to 4 years. Cancers identified in second and subsequent screening rounds tended to be small with favourable histological grading, and with a low probability (about 1 in 10) of becoming clinically important in the man\'s lifetime ([@bib44]). The CAP trial aims to assess the impact of single PSA testing, allowing the lifetime risk of developing clinically important prostate cancer amongst men initially screen negative to be quantified, and contributing natural history data to the debate on whether a single PSA measurement in middle age could be used to risk stratify men for further PSA testing and targeted treatment ([@bib48]). It is possible that a single screen may underestimate the potential long-term benefits of a PSA-testing programme with multiple rounds ([@bib22]), as investigated in the ERSPC and other trials, and might be considered difficult to implement in countries with established PSA-testing programmes. A single PSA test, however, is less likely to identify large numbers of clinically insignificant disease ([@bib23]). In the UK, a previously unscreened population, the pool of clinically significant disease will be larger than in a population already undergoing regular screening. The trial design, therefore, will determine the effectiveness of a single PSA test while minimising the negative public health consequences of identifying clinically insignificant disease.

Misattribution of cause of death ([@bib1]; [@bib7]) is an important potential source of bias in trials with cancer-specific mortality as the primary end point. Small inaccuracies in attributing cause of death can have the potential to alter the results if misclassification is differential between study arms. To minimise misclassification of cause of death, possible prostate cancer deaths are reviewed by an independent international cause of death committee blinded to the trial arms, with an embedded quality assurance process to ensure the reliability of the vignettes and the decisions of the reviewers (data to be presented separately).

We are powered to detect an overall prostate cancer mortality rate ratio of 0.87 (13% relative reduction). Reductions in prostate cancer mortality of the order of 15--20% are likely to be important to the NHS. Although our estimates suggest the effect of contamination is minimal unless it reaches 20%, the power of the trial will be reduced if men in the control practices are screened for prostate cancer ('contamination\'). An advantage of the cluster randomised design is that contamination is likely to be less of a problem than would be the case if men were individually randomised, and hence were alerted to the possibility of being screened for prostate cancer.

The CAP and ProtecT trials have been designed and conducted to make a much awaited and crucial contribution in understanding the effectiveness and cost-effectiveness of prostate cancer screening, as well as directly informing international policy on testing and treatment of this common malignancy.
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![**Consort diagram for recruitment into the Cluster Randomised Trial of Testing for Prostate Cancer (CAP), England and Wales.** ^a^Explicit refusal=refused to participate. ^b^Implicit refusal=no definitive response given to invitation to participate. ^c^Includes *n*=6581 pseudo-anonymised follow-up for mortality and prostate cancer. \*Figures as of June 2013, subject to small changes over time because of continued updates from the Health and Social Care Information Centre, eg, to remove newly identified duplicates or changes to trace status.](bjc2014242f2){#fig2}

###### Comparison of baseline characteristics between participating intervention and control arm practices, England and Wales

                                                                **Intervention arm (*****n*****=271)**   **Control arm (*****n*****=302)**   ***P*****-value for difference**[a](#t1-fn2){ref-type="fn"}
  ------------------------------------------------------------- ---------------------------------------- ----------------------------------- -------------------------------------------------------------
  Mean practice list size (s.d.)                                6883 (3442)                              6777 (3707)                         0.7
  Number of urban practices[b](#t1-fn3){ref-type="fn"} (%)      267 (88%)                                267 (88%)                           0.8
  **Indicies of deprivation**                                                                                                                
  Mean IMD score[c](#t1-fn4){ref-type="fn"} in England (s.d.)   28 (19)                                  30 (19)                             0.2
  Mean IMD score[d](#t1-fn5){ref-type="fn"} in Wales (s.d.)     21 (14)                                  22 (16)                             0.7
  **Mean prevalence from QOF**                                                                                                               
  All cancers[e](#t1-fn6){ref-type="fn"} (s.e.)                 0.57% (0.02%)                            0.53% (0.01%)                       0.07
  Diabetes (s.e.)                                               3.6% (0.07%)                             3.7% (0.06%)                        0.4
  Obesity (s.e.)                                                8.0% (0.2%)                              7.8% (0.2%)                         0.3
  Coronary heart disease (s.e.)                                 4.1% (0.09%)                             3.9% (0.08%)                        0.2

Abbreviations: IMD=index of multiple deprivation; QOF=quality outcomes framework; s.d.=standard deviaton; s.e.=standard error.

*P*-values were calculated using Robust Regression, all analyses adjusted for geographic and primary care grouping.

Rural/urban classification 2004 (scale: 1:urban; 2:town and fringe; 3:village; 4:hamlet and isolated dwellings).

2004 and

2005 (higher scores indicate greater levels of deprivation).

Prevalence of cancer from quality outcomes framework 2004/5 where available (*n*=491).

###### Comparison of the major design characteristics of the Cluster randomised triAl of PSA testing for Prostate cancer, European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal and Ovary (PLCO) trials

                                        **Cluster randomised triAl of PSA testing for Prostate cancer**                                     **European Randomized Study of Screening for Prostate Cancer**                                                                                                                                                                                 **Prostate, Lung, Colorectal and Ovary Trials**
  ------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Age range (years)                     50--69                                                                                              55--69 (core group) Some 50--54, 70--74                                                                                                                                                                                                        55--74
  **Randomisation**                                                                                                                                                                                                                                                                                                                                                                        
  Randomisation unit                    General practice                                                                                    Individual                                                                                                                                                                                                                                     Individual
  Randomisation process                 All men at participating general practices were randomised (population-based effectiveness trial)   In Netherlands, Belgium, Switzerland, Spain, only men giving consent underwent randomisation (efficacy trial).In Finland, Sweden and Italy, all men identified from cancer registries were randomised (population-based effectiveness trial)   Only men giving informed consent were randomised (efficacy trial)
  **Detection**                                                                                                                                                                                                                                                                                                                                                                            
  Prostate-specific antigen threshold   3.0 ng ml^−1^                                                                                       3.0 ng ml^−1^ or 4.0 ng ml^−1^ (varies by centre)                                                                                                                                                                                              4.0 ng ml^−1^
  Biopsy protocol                       10-core transrectal ultrasound-guided biopsy                                                        Majority of centres used sextant biopsies guided by transrectal ultrasound                                                                                                                                                                     Diagnostic evaluation decided by the patients and their primary physicians.
  Screening interval                    Single screen                                                                                       4-yearly (some 2 years)                                                                                                                                                                                                                        1 year
  **Treatment and outcome**                                                                                                                                                                                                                                                                                                                                                                
  Treatment regimen in screened group   Randomised (surgery, radiotherapy, active monitoring)                                               Variable usual care (radical advised)                                                                                                                                                                                                          Variable usual care (radical advised)
  Outcome ascertainment                 Independent blinded adjudication committee                                                          Blinded committee (some centres death certification)                                                                                                                                                                                           Blinded reviewers (prostate cancer-specific death)
